{"prompt": "['REDUCING IMMUNOGENICITY TO', 'PEGLOTICASE (RECIPE)', 'National Clinical Trial (NCT) Identified Number: NCT03303989', 'Principal Investigator: Kenneth G. Saag, MD, MSc', 'IND/IDE Sponsor: University of Alabama at Birmingham', 'Funded by: National Institute of Arthritis and Musculoskeletal and Skin Diseases and Horizon Pharma,', 'PLC', 'Version Number: 12.0', '01/13/2020']['Table of Contents', '1', 'STATEMENT OF COMPLIANCE', '1', '2.1', 'Synopsis', '1', '2.2', 'Schema', '2', '2.3', 'Table 1. Schedule of Activities (SoA)', '0', '3', 'INTRODUCTION', '0', '3.1', 'Study Rationale', '0', '3.2', 'Background', '0', '3.3', 'Risk/Benefit Assessment', '1', '3.3.1', 'Known Potential Risks', '1', '3.3.2', 'Known Potential Benefits', '3', '3.3.3', 'Assessment of Potential Risks and Benefits', '3', '4', 'OBJECTIVES AND ENDPOINTS', '4', '5', 'STUDY DESIGN', '5', '5.1', 'Overall Design', '5', '5.2', 'Scientific Rationale for Study Design', '5', '5.2.1', 'Rationale for a Pegloticase Immunogenicity Trial', '5', '5.2.2', 'Rationale for Mycophenolate Mofetil (MMF) as the Preferred Immune', 'Modulating Agent 6', '5.3', 'Justification for Dose', '7', '5.4', 'End of Study Definition', '7', '6', 'STUDY POPULATION', '7', '6.1', 'Inclusion Criteria', '7', '6.2', 'Exclusion Criteria', '7', '6.3', 'Lifestyle Considerations', '8', '6.4', 'Screen Failures', '9', '6.5', 'Strategies for Recruitment and Retention', '9', '7', 'STUDY INTERVENTION', '9', '7.1', 'Study Intervention(s) Administration', '10', '7.1.1', 'Study Intervention Description overview', '10', '7.1.2', 'Dosing and Administration of study drugs', '10', '7.2', 'Preparation/Handling/Storage/Accountability of study drugs', '11', '7.2.1', 'Acquisition and accountability', '11', '7.2.2', 'Formulation, Appearance, Packaging, and Labeling', '12', '7.2.3', 'Product Storage and Stability', '12', '7.2.4', 'Product Destruction', '13', '7.2.5', 'Preparation', '13', '7.3', 'Measures to Minimize Bias: Randomization and Blinding', '13', '7.4', 'Study Intervention Compliance', '13', '7.5', 'Concomitant Therapy', '14', '7.5.1', 'Rescue Medicine', '14', '8', 'STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT', 'DISCONTINUATION/WITHDRAWAL', '14', '8.1', 'Discontinuation of Study Intervention', '14', '8.2', 'Participant Discontinuation/Withdrawal from the Study', '15', '8.3', 'Lost to Follow-Up', '15', '9', 'STUDY ASSESSMENTS AND PROCEDURES', '16', '9.1', 'Efficacy Assessments', '25', 'ii']['9.2', 'Safety and Other Assessments', '25', '9.3', 'Adverse Events and Serious Adverse Events', '26', '9.3.1', 'Definition of Adverse Events (AE)', '26', '9.3.2', 'Definition of Serious Adverse Events (SAE)', '26', '9.3.3', 'Classification of an Adverse Event', '27', '9.3.4', 'Time Period and Frequency for Event Assessment and Follow-Up', '29', '9.3.5', 'Adverse Event Reporting', '30', '9.3.6', 'SeRIOUS ADVerse Event Reporting', '30', '9.3.7', 'Reporting Events to Participants', '30', '9.3.8', 'Events of Special Interest', '30', '9.4', 'Unanticipated Problems', '31', '9.4.1', 'Definition of Unanticipated Problems (UP)', '31', '9.4.2', 'Unanticipated Problem Reporting', '32', '9.4.3', 'Reporting Unanticipated Problems to Participants', '32', '10', 'STATISTICAL CONSIDERATIONS', '32', '10.1', 'Statistical Hypotheses', '32', '10.2', 'Sample Size Determination', '32', '10.3', 'Populations for Analyses', '32', '10.4', 'Statistical Analyses', '33', '10.4.1', 'General Approach', '33', '10.4.2', 'Analysis of the Primary Efficacy Endpoint(s)', '34', '10.4.3', 'Analysis of the Primary SAfety and Secondary Endpoint(s)', '34', '10.4.4', 'Baseline Descriptive Statistics', '35', '10.4.5', 'Interim Analyses', '35', '10.4.6', 'Sub-Group Analyses', '35', '10.4.7', 'Missing data and outliers', '35', '11', 'SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS', '36', '11.1', 'Regulatory, Ethical, and Study Oversight Considerations', '36', '11.1.1', 'Informed Consent Process', '36', '11.1.2', 'Study Discontinuation and Closure', '36', '11.1.3', 'Confidentiality and Privacy', '37', '11.1.4', 'Future Use of Stored Specimens and Data', '37', '11.1.5', 'Key Roles and Study Governance', '38', '11.1.6', 'Safety Oversight', '38', '11.1.7', 'Clinical Monitoring', '38', '11.1.8', 'Quality Assurance and Quality Control', '40', '11.1.9', 'Data Handling and Record Keeping', '40', '11.1.10', 'Protocol Deviations', '40', '11.1.11', 'Publication and Data Sharing Policy', '41', '11.1.12', 'Conflict of Interest Policy', '41', '11.2', 'Additional Considerations', '41', '11.3', 'Abbreviations', '41', '11.4', 'Protocol Amendment History', '43', '12', 'REFERENCES', '46', 'iii']\n\n###\n\n", "completion": "END"}